American Medicare deal for Tissue Regenix

TISSUE REGENIX, the medical devices firm which commercialises academic research conducted by its partners around the world, has secured a £400,000 deal in the USA.

In March the York group secured approval from Novitas, which administers Medicare in a number of US states and is responsible for product coverage and reimbursement.

Today’s announcement is for a contract with a surgical and wound care distribution network that covers two of the 12 states that are covered by the Novitas reimbursement notice, representing nearly 1m Medicare patients. It is expected to be worth at least $600,000 (£400,000) in the next year.

Antony Odell, chief executive of Tissue Regenix, said: “Our US team has done an outstanding job in achieving commercial traction for DermaPure and signing this regional distribution agreement. This agreement validates the hard work put in since the launch of DermaPure in June 2014, as well as the remarkable clinical results that we are seeing from the product.”